IN2015KN00074A - - Google Patents

Info

Publication number
IN2015KN00074A
IN2015KN00074A IN74KON2015A IN2015KN00074A IN 2015KN00074 A IN2015KN00074 A IN 2015KN00074A IN 74KON2015 A IN74KON2015 A IN 74KON2015A IN 2015KN00074 A IN2015KN00074 A IN 2015KN00074A
Authority
IN
India
Prior art keywords
adeno
nucleotides
disclosed
length
nucleic acid
Prior art date
Application number
Other languages
English (en)
Inventor
Beverly L Davidson
Maria Scheel
Ryan Boudreau
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of IN2015KN00074A publication Critical patent/IN2015KN00074A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN74KON2015 2012-07-06 2013-03-14 IN2015KN00074A (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261668839P 2012-07-06 2012-07-06
PCT/US2013/031644 WO2014007858A1 (en) 2012-07-06 2013-03-14 Modified adeno-associated virus vector compositions

Publications (1)

Publication Number Publication Date
IN2015KN00074A true IN2015KN00074A (cg-RX-API-DMAC10.html) 2015-07-31

Family

ID=49882407

Family Applications (1)

Application Number Title Priority Date Filing Date
IN74KON2015 IN2015KN00074A (cg-RX-API-DMAC10.html) 2012-07-06 2013-03-14

Country Status (12)

Country Link
US (2) US9540659B2 (cg-RX-API-DMAC10.html)
EP (1) EP2870237B1 (cg-RX-API-DMAC10.html)
JP (1) JP6366581B2 (cg-RX-API-DMAC10.html)
CN (1) CN104619832B (cg-RX-API-DMAC10.html)
AU (1) AU2013287261B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015000161A2 (cg-RX-API-DMAC10.html)
CA (1) CA2878401C (cg-RX-API-DMAC10.html)
ES (1) ES2703177T3 (cg-RX-API-DMAC10.html)
HK (1) HK1210214A1 (cg-RX-API-DMAC10.html)
IN (1) IN2015KN00074A (cg-RX-API-DMAC10.html)
RU (1) RU2679843C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014007858A1 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1210214A1 (en) * 2012-07-06 2016-04-15 University Of Iowa Research Foundation Modified adeno-associated virus vector compositions
AU2015264263B2 (en) * 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2017023724A1 (en) * 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
AU2017234929B2 (en) * 2016-03-18 2024-05-02 The Children's Hospital Of Philadelphia Therapeutic for treatment of diseases including the central nervous system
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
AU2018383712B2 (en) * 2017-12-11 2025-09-04 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
WO2019152841A1 (en) 2018-02-01 2019-08-08 Homology Medicines, Inc. Adeno-associated virus compositions for pah gene transfer and methods of use thereof
AU2019215152A1 (en) 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US20210254103A1 (en) * 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
MX2021013913A (es) 2019-05-14 2022-03-17 Univ Duke Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
WO2021011841A1 (en) * 2019-07-18 2021-01-21 Lysogene Compositions and methods for the treatment of sanfilippo disease and other disorders
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
WO2021231305A2 (en) * 2020-05-11 2021-11-18 Gordian Biotechnology, Inc. Viral delivery vehicle selection
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
AU2022218196A1 (en) * 2021-02-05 2023-08-10 Maze Therapeutics, Inc. Vectors comprising stuffer polynucleotide sequences
EP4334454A2 (en) * 2021-05-04 2024-03-13 RegenxBio Inc. Novel aav vectors and methods and uses thereof
KR20250048560A (ko) * 2022-08-09 2025-04-09 유니버시티 오브 셰프필드 바이러스 벡터

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JPH1033175A (ja) * 1996-07-24 1998-02-10 Hisamitsu Pharmaceut Co Inc 組換えアデノ随伴ウイルスベクターの製造方法
US6171855B1 (en) * 1998-05-28 2001-01-09 The Regents Of The University Of Michigan Vectors
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CN1183257C (zh) * 1999-10-29 2005-01-05 宝生物工程株式会社 基因转移的方法
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
US7387896B2 (en) * 2003-03-26 2008-06-17 The Regents Of The University Of Michigan MicroRNA vectors
AU2004283053A1 (en) * 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
WO2009134681A2 (en) * 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
CA3050894C (en) * 2010-04-23 2022-10-18 University Of Massachusetts Multicistronic expression constructs
ES2739804T3 (es) 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
HK1210214A1 (en) * 2012-07-06 2016-04-15 University Of Iowa Research Foundation Modified adeno-associated virus vector compositions

Also Published As

Publication number Publication date
EP2870237B1 (en) 2018-09-26
JP6366581B2 (ja) 2018-08-08
CA2878401A1 (en) 2014-01-09
EP2870237A4 (en) 2015-12-23
US9540659B2 (en) 2017-01-10
CN104619832B (zh) 2021-03-16
EP2870237A1 (en) 2015-05-13
RU2015103901A (ru) 2016-08-27
US20150184197A1 (en) 2015-07-02
AU2013287261A1 (en) 2015-01-22
BR112015000161A2 (pt) 2017-06-27
CA2878401C (en) 2022-07-19
HK1210214A1 (en) 2016-04-15
RU2679843C2 (ru) 2019-02-13
WO2014007858A1 (en) 2014-01-09
ES2703177T3 (es) 2019-03-07
CN104619832A (zh) 2015-05-13
JP2015522280A (ja) 2015-08-06
AU2013287261B2 (en) 2019-03-07
US20170306355A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
HK1210214A1 (en) Modified adeno-associated virus vector compositions
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
IL241294A0 (en) Genetic expression of response in dendritic cells, preparations and methods of use
IL240881A0 (en) Expression of the t cell balance gene, preparations, materials and methods for its use
ZA201507006B (en) Compositions and methods of nucleic acid-targeting nucleic acids
ZA201507605B (en) Ribonucleic acids with 4'-thio-modified nucleotides and related methods
EP3080289A4 (en) Modified nucleic acid molecules and uses thereof
IL245839A0 (en) Inhibitors of rna polymerase i and use of preparations containing them for treatment
IL245674A0 (en) Methods and preparations for the targeted modification of a genome
ZA201408764B (en) Compositions and methods for silencing gene expression
ZA201506682B (en) Compositions and methods for the improved production and delivery of rna
EP3033325A4 (en) Compositions and methods for delivering messenger rna
IL241269A0 (en) Amplification of nucleic acids
SG11201602331QA (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
SG11201602291TA (en) Nucleic acid biomarker and use thereof
PL2988764T3 (pl) Kompozycje przeciwłupieżowe i sposoby ich zastosowania
ZA201600024B (en) Methods and compositions for templated assembly of nucleic acid specific heterocompounds
IL245123A0 (en) Short interfering RNA and its use in methods and preparations for preventing the expression of the orai1 gene
EP2925893A4 (en) COMPOSITIONS AND METHODS FOR THE PREPARATION OF NUCLEIC ACID AND ANALYZES
GB201211775D0 (en) An electrode and use thereof
EP3078747A4 (en) Peanut-binding nucleic acid molecule and use thereof
Haslam et al. IN SEARGH OF Charisma
IL235426A0 (en) Nucleic acid structure and its use
IL233475A0 (en) Carbocyclic nucleosides, preparations containing them and their uses
HRP20181632T1 (hr) Postupci i kompoziti za ciljanu modificiranje genoma